Literature DB >> 32003661

Thrombospondin-1 as a Potential Therapeutic Target: Multiple Roles in Cancers.

Pengfei Wang1,2,3, Zheng Zeng1,2,3, Caiji Lin1,2,3, Jiali Wang1,2,3, Wenwen Xu1,2,3, Wenqing Ma1,2,3, Qian Xiang1,2,3, Huidi Liu1,2,3,4,5, Shu-Lin Liu1,2,3,5.   

Abstract

Thrombospondin-1, an extracellular matrix protein, is the first identified natural angiogenesis inhibitor. Thrombospondin-1 participates in a great number of physiological and pathological processes, including cell-cell and cell-matrix interactions via a number of cell receptors, including CD36 and CD47, which plays a vital role in mediating inflammation and performs a promoting effect in pulmonary arterial vasculopathy and diabetes. Thrombospondin-1 consists of six domains, which combine with different molecules and participate in various functions in cancers, serving as a critical member in diverse pathways in cancers. Thrombospondin-1 works as a cancer promotor in some pathways but as a cancer suppressor in others, which makes it highly possible that its erroneous functioning might lead to opposite effects. Therefore, subdividing the roles of thrombospondin-1 and distinguishing them in cancers are necessary. Complex structure and multiple roles take disadvantage of the research and application of thrombospondin-1. Compared with the whole thrombospondin-1 protein, each thrombospondin- 1 active peptide performs an uncomplicated structure and, nevertheless, a specific role. In other words, various thrombospondin-1 active peptides may function differently. For instance, thrombospondin-1 could both promote and inhibit glioblastoma, which is significantly inhibited by the three type I repeats, a thrombospondin-1 active peptide but promoted by the fragment 167-569, a thrombospondin-1 active peptide consisting of the procollagen homology domain and the three type I repeats. Further studies of the functions of thrombospondin-1 active peptides and applying them reasonably are necessary. In addition to mediating cancerogenesis, thrombospondin-1 is also affected by cancer development, as reflected by its expression in plasma and the cancer tissue. Therefore, thrombospondin-1 may be a potential biomarker for pre-clinical and clinical application. This review summarizes findings on the multiple roles of thrombospondin-1 in cancer processes, with a focus on its use as a potential therapeutic target. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Thrombospondin-1; active peptide; biomarker; cancer; cancer promotor; cancer suppressor; therapeutic target.

Mesh:

Substances:

Year:  2020        PMID: 32003661     DOI: 10.2174/1381612826666200128091506

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  Isthmin 2 is decreased in preeclampsia and highly expressed in choriocarcinoma.

Authors:  Cynthia Martinez; Javier González-Ramírez; María E Marín; Gustavo Martínez-Coronilla; Vanessa I Meza-Reyna; Rafael Mora; Raul Díaz-Molina
Journal:  Heliyon       Date:  2020-10-13

2.  Cloning, Expression and Inhibitory Effects on Lewis Lung Carcinoma Cells of rAj-Tspin from Sea Cucumber (Apostichopus japonicus).

Authors:  Rong Qiao; Rong Xiao; Zhong Chen; Jingwei Jiang; Chenghua Yuan; Shuxiang Ning; Jihong Wang; Zunchun Zhou
Journal:  Molecules       Date:  2021-12-30       Impact factor: 4.411

3.  Exosomes produced by melanoma cells significantly influence the biological properties of normal and cancer-associated fibroblasts.

Authors:  Karolína Strnadová; Lucie Pfeiferová; Petr Přikryl; Barbora Dvořánková; Erik Vlčák; Jana Frýdlová; Martin Vokurka; Jiří Novotný; Jana Šáchová; Miluše Hradilová; Jan Brábek; Jana Šmigová; Daniel Rösel; Karel Smetana; Michal Kolář; Lukáš Lacina
Journal:  Histochem Cell Biol       Date:  2021-11-27       Impact factor: 4.304

4.  High Expression of THBS1 Leads to a Poor Prognosis in Papillary Thyroid Cancer and Suppresses the Anti-Tumor Immune Microenvironment.

Authors:  Anqi Jin; Jin Zhou; Pengcheng Yu; Shichong Zhou; Cai Chang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

5.  Precision N-glycoproteomics reveals elevated LacdiNAc as a novel signature of intrahepatic cholangiocarcinoma.

Authors:  Jun Li; Ting Zhao; Jing Li; Jiechen Shen; Li Jia; Bojing Zhu; Liuyi Dang; Chen Ma; Didi Liu; Fan Mu; Liangshuo Hu; Shisheng Sun
Journal:  Mol Oncol       Date:  2021-12-18       Impact factor: 7.449

Review 6.  Fatty Acids, CD36, Thrombospondin-1, and CD47 in Glioblastoma: Together and/or Separately?

Authors:  Cristiana Tanase; Ana Maria Enciu; Elena Codrici; Ionela Daniela Popescu; Maria Dudau; Ana Maria Dobri; Sevinci Pop; Simona Mihai; Ancuța-Augustina Gheorghișan-Gălățeanu; Mihail Eugen Hinescu
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.